Artificial intelligence is a great tendency to care for cancer, and is mainly focused on detecting cancer at the fastest possible stage. This makes a lot of sense, given that cancer is less deadly as soon as possible.
But less are asking another basic question: if someone has cancer, is an aggressive treatment like chemotherapy is needed? This is the problem that Ataracia he is trying to solve.
New York -based start has focused on using it to predict not only if a patient has cancer, but also what their cancer result looks like in 5 to 10 years. If there is only a little chance for cancer to return, chemistry can be avoided completely – saving a lot of money, avoiding the infamous side effects of treatment.
Ataraxis he now plans to start their first trading test, for breast cancer, for us oncologists in the coming months, tells its co -founder Jan Witowski. To strengthen the start and expansion in other types of cancer, the start has set up a $ 20.4 million series, Techcrunch told exclusively.
The round was led by Aix Ventures with participation by Thiel Bio, Founder Funders, Floating Point, Bertelsmann and existing Giant Ventures and Ventures investors. Ataraxis came out of stealing last year with a seed of $ 4 million.
Ataraxis was founded by Witowski and Krzysztof Geras, an assistant professor at the NYU Medical School who focuses on him.
Ataraxis technology has been powered by a model that derives information from high -resolution images of carcinogenic cells. The model is trained in hundreds of millions of true images from thousands of patients, Witowski said. A recent study showed that Ataraxis technology was 30% more accurate than the current standard of breast cancer care for Ataraxis.
Long -term, Ataraxis has great ambitions. He wants her tests to affect at least half of the new cases of cancer by 2030. He also sees himself as a border company that builds its own models, looking for the head of the meta scientists, Yann Lecun as a councilor.
“I think at Atharaxis we are trying to build what is essentially a Laboratory that Frontier, but for health care applications,” Witowski said. “Because so many of those problems require a very new technology.”
He has led to a hurry on funding for cancer care. Valar Labs set up $ 22 million to help patients understand their treatment plan in May 2024, for example. There is also a Bevvy of drug detection firms with him in the cancer space, such as Manas who collected $ 24.6 million in January 2025 and was founded by Reid Hoffman, co -founder of Linkedin.
